Celcuity (NASDAQ:CELC) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Celcuity (NASDAQ:CELC) from a hold rating to a buy rating in a research note released on Thursday, Zacks.com reports. They currently have $25.00 price target on the stock.

According to Zacks, “Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular activity driving a patient’s cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. “

CELC has been the topic of several other research reports. HC Wainwright set a $36.00 target price on shares of Celcuity and gave the company a buy rating in a research note on Wednesday, May 8th. ValuEngine cut shares of Celcuity from a buy rating to a hold rating in a research note on Wednesday, May 8th.

CELC traded down $1.00 during midday trading on Thursday, hitting $22.08. 1,782 shares of the company traded hands, compared to its average volume of 5,453. The company has a debt-to-equity ratio of 0.01, a quick ratio of 26.94 and a current ratio of 26.94. The firm has a 50-day moving average of $22.38. Celcuity has a 52 week low of $18.31 and a 52 week high of $31.00.

Celcuity (NASDAQ:CELC) last posted its earnings results on Tuesday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. Research analysts forecast that Celcuity will post -0.81 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of CELC. BNP Paribas Arbitrage SA increased its position in shares of Celcuity by 13,655.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,238 shares of the company’s stock valued at $27,000 after purchasing an additional 1,229 shares during the last quarter. Nelson Roberts Investment Advisors LLC purchased a new stake in shares of Celcuity during the 1st quarter valued at about $115,000. Kessler Investment Group LLC increased its position in shares of Celcuity by 46.3% during the 1st quarter. Kessler Investment Group LLC now owns 7,017 shares of the company’s stock valued at $154,000 after purchasing an additional 2,222 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Celcuity by 9.1% during the 4th quarter. Geode Capital Management LLC now owns 35,035 shares of the company’s stock valued at $840,000 after purchasing an additional 2,930 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Celcuity by 2.0% during the 4th quarter. Northern Trust Corp now owns 61,888 shares of the company’s stock valued at $1,484,000 after purchasing an additional 1,223 shares during the last quarter. Institutional investors and hedge funds own 22.04% of the company’s stock.

About Celcuity

Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.

Featured Article: How do candlesticks reflect price movement?

Get a free copy of the Zacks research report on Celcuity (CELC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.